Portal de Periódicos da CAPES

Effect of selective LRRK2 kinase inhibition on nonhuman primate lung

2015; American Association for the Advancement of Science; Volume: 7; Issue: 273 Linguagem: Inglês

10.1126/scitranslmed.aaa3634

1946-6242

Reina N. Fuji, Michael Flagella, Miriam Baca, Marco A. S. Baptista, Jens Brodbeck, Bryan Chan, Brian Fiske, Lee Honigberg, Adrian M. Jubb, Paula Katavolos, Donna W. Lee, Sock-Cheng Lewin-Koh, Tori Lin, Xingrong Liu, Shannon Liu, Joseph P. Lyssikatos, Jennifer O’Mahony, Mike Reichelt, Merone Roose‐Girma, Zejuan Sheng, Todd Sherer, Ashley Smith, Margaret Solon, Zachary K. Sweeney, Jacqueline M. Tarrant, Alison Urkowitz, Søren Warming, Murat Yaylaoglu, Shuo Zhang, Haitao Zhu, Anthony A. Estrada, Ryan J. Watts,

Alzheimer's disease research and treatments

LRRK2 kinase inhibitors, under development for Parkinson’s disease, have an effect on type II pneumocytes in nonhuman primate lung, suggesting that pulmonary toxicity may be a critical safety liability.